Scilex Holding Company (SCLX)
SCLX Stock Price Chart
Explore Scilex Holding Company interactive price chart. Choose custom timeframes to analyze SCLX price movements and trends.
SCLX Company Profile
Discover essential business fundamentals and corporate details for Scilex Holding Company (SCLX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
5 Mar 2021
Employees
115.00
Website
https://www.scilexholding.comCEO
Henry H. Ji
Description
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
SCLX Financial Timeline
Browse a chronological timeline of Scilex Holding Company corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.18, while revenue estimate is $16.00m.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.29, while revenue estimate is $16.00m.
Earnings released on 20 May 2026
EPS came in at -$4.76 falling short of the estimated -$0.21 by -2.17k%, while revenue for the quarter reached $8.61m , missing expectations by -42.58%.
Earnings released on 10 Apr 2026
EPS came in at -$4.60 falling short of the estimated -$0.29 by -1.47k%, while revenue for the quarter reached $4.79m , missing expectations by -60.39%.
Earnings released on 14 Nov 2025
EPS came in at -$22.17 falling short of the estimated -$0.47 by -4.62k%, while revenue for the quarter reached $10.56m , missing expectations by -12.73%.
Earnings released on 13 Aug 2025
EPS came in at -$7.42 falling short of the estimated -$0.41 by -1.71k%, while revenue for the quarter reached $9.90m , missing expectations by -62.30%.
Earnings released on 14 May 2025
EPS came in at -$2.26 surpassing the estimated -$4.20 by +46.19%, while revenue for the quarter reached $5.00m , meeting expectations.
Stock split effective on 15 Apr 2025
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2025
EPS came in at -$0.25 falling short of the estimated -$0.10 by -150.00%, while revenue for the quarter reached $14.90m , missing expectations by -16.24%.
Earnings released on 17 Jan 2025
EPS came in at -$6.29 falling short of the estimated -$0.17 by -3.60k%, while revenue for the quarter reached $14.44m , missing expectations by -19.21%.
Earnings released on 13 Aug 2024
EPS came in at -$6.29 surpassing the estimated -$6.99 by +10.01%, while revenue for the quarter reached $16.37m , beating expectations by +1.25%.
Earnings released on 13 May 2024
EPS came in at -$9.09 falling short of the estimated -$4.20 by -116.43%, while revenue for the quarter reached $10.88m , meeting expectations.
Earnings released on 11 Mar 2024
EPS came in at -$8.74 falling short of the estimated -$7.34 by -19.07%, while revenue for the quarter reached $13.46m , beating expectations by +17.82%.
Earnings released on 14 Nov 2023
EPS came in at -$22.03 falling short of the estimated -$5.94 by -270.88%, while revenue for the quarter reached $10.12m , missing expectations by -10.99%.
Earnings released on 11 Aug 2023
EPS came in at -$5.59 , while revenue for the quarter reached $12.58m .
Earnings released on 12 May 2023
EPS came in at -$0.22 , while revenue for the quarter reached $10.58m .
Earnings released on 7 Mar 2023
EPS came in at -$4.66 , while revenue for the quarter reached $11.92m .
Earnings released on 30 Sept 2022
EPS came in at $5.65 , while revenue for the quarter reached $11.38m .
Earnings released on 30 Jun 2022
EPS came in at -$4.42 , while revenue for the quarter reached $7.93m .
Earnings released on 31 Mar 2022
EPS came in at -$2.27 , while revenue for the quarter reached $6.81m .
Earnings released on 31 Dec 2021
EPS came in at $0.26 , while revenue for the quarter reached $8.26m .
Earnings released on 30 Sept 2021
EPS came in at -$0.33 , while revenue for the quarter reached $8.32m .
SCLX Stock Performance
Access detailed SCLX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
